{"database": "lobbying", "table": "lobbying_activities", "rows": [[2060364, "d7e34f15-2379-460b-847a-50fd96fc6ed5", "Q4", "FARRAGUT PARTNERS LLP", 401103938, "ASTRAZENECA PHARMACEUTICALS LP", 2017, "fourth_quarter", "MMM", "Medicare Part B and FDA. Cancer Payment Reform Legislation S. 462. Issues related to the 340B Drug discount program. CHIP reauthorization.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2018-01-11T14:09:04.377000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2060364"], "units": {}, "query_ms": 281.2965880148113, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}